About 200 Mg Rucaparib Tablets
Experience instant savings with top-ranking 200 mg Rucaparib Tablets, designed for sublime efficacy in ovarian and prostate cancer therapy. Each immaculate, blue, film-coated, oval tablet offers targeted anti-cancer activity with proven FDA, EU, and IN approvals. Available in convenient packs of 60 or 120 tablets, these orally administered tablets suit adult patients and feature a clearly marked "200" imprint. Buy with confidence from India's leading distributor, exporter, and supplier. Proper storage below 30C and a 24-month shelf life ensure product integrity. Prescription only.
Features & Application of 200 Mg Rucaparib Tablets
Rucaparib Tablets, 200 mg, represent a targeted cancer treatment option leveraging PARP enzyme inhibition. The plant application focuses on streamlined production to support oncology needs, supplying sublime precision for adult patients. Major areas of application include ovarian and prostate cancer, where high purity and immaculate formulation offer distinct therapeutic benefits. Engineered for oral use, each batch embodies high standards, delivering reliable and efficient anti-cancer activity as part of sophisticated treatment regimens.
Export Market, Packaging & Drop-off for 200 Mg Rucaparib Tablets
Servicing the main domestic market and tapping into international export opportunities, our 200 mg Rucaparib Tablets are meticulously packed for optimum valuation and global shipment. Secure drop-off is ensured through robust, moisture-resistant packaging that preserves quality throughout transit. We offer adaptable packaging details, catering to packs of 60 or 120 tablets. FOB Port India provides a reliable export gateway, making these top tablets accessible worldwide to meet both local and international demand.
FAQ's of 200 Mg Rucaparib Tablets:
Q: How should 200 mg Rucaparib Tablets be stored for optimal effectiveness?
A: Store the tablets below 30C, protected from moisture, to maintain their pristine quality and extend shelf life up to 24 months.
Q: What is the main therapeutic application of Rucaparib 200 mg Tablets?
A: Rucaparib 200 mg Tablets are primarily indicated for treating ovarian and prostate cancer in adults through targeted inhibition of the PARP enzyme.
Q: When are Rucaparib Tablets contraindicated?
A: These tablets are contraindicated in patients with known hypersensitivity to Rucaparib or any of its excipients.
Q: Where do these tablets hold regulatory approval?
A: They are approved by the regulatory authorities in the FDA, EU, and India; refer to the packaging for precise details.
Q: What common side effects should patients expect during usage?
A: Commonly reported side effects include nausea, fatigue, vomiting, anemia, and abdominal pain; consult your healthcare provider for full details.
Q: How does the export process secure product integrity for international markets?
A: Products are packed in robust, moisture-protected packaging and shipped via India's reliable FOB ports, ensuring secure drop-off and product quality on arrival.